Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles

[1]  Daniel Bell.  Lymphopenia , 2020, Radiopaedia.org.

[2]  F. Rieux-Laucat,et al.  Monitoring Disease Activity in Systemic Lupus Erythematosus With Single‐Molecule Array Digital Enzyme‐Linked Immunosorbent Assay Quantification of Serum Interferon‐α , 2019, Arthritis & rheumatology.

[3]  L. Magder,et al.  Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus , 2019, BMC Medical Genomics.

[4]  P. Emery,et al.  Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status , 2018, Annals of the rheumatic diseases.

[5]  P. Emery,et al.  A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features , 2018, Scientific Reports.

[6]  M. Alarcón‐Riquelme,et al.  Moving towards a molecular taxonomy of autoimmune rheumatic diseases , 2018, Nature Reviews Rheumatology.

[7]  S. Kamphuis,et al.  Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors? , 2018, Arthritis Research & Therapy.

[8]  F. Rieux-Laucat,et al.  Detection of interferon alpha protein reveals differential levels and cellular sources in disease , 2017, The Journal of experimental medicine.

[9]  J. Wither,et al.  Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis , 2017, Arthritis Research & Therapy.

[10]  P. J. van der Spek,et al.  Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndrome , 2016, Annals of the rheumatic diseases.

[11]  Hedi Peterson,et al.  AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies , 2016, Cell.

[12]  Virginia Pascual,et al.  Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients , 2016, Cell.

[13]  Virginia Pascual,et al.  Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients , 2016, Cell.

[14]  C. Wouters,et al.  Spondyloenchondrodysplasia Due to Mutations in ACP5: A Comprehensive Survey , 2016, Journal of Clinical Immunology.

[15]  C. Mainero,et al.  Interferon-β therapy and risk of thrombocytopenia in multiple sclerosis patients , 2015, Journal of the Neurological Sciences.

[16]  Y. Crow,et al.  Aicardi–Goutières syndrome and the type I interferonopathies , 2015, Nature Reviews Immunology.

[17]  Christina Chaivorapol,et al.  Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE , 2015, Lupus Science & Medicine.

[18]  L. Lagae,et al.  Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling , 2014, Nature Genetics.

[19]  A. Vanderver,et al.  Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study , 2013, The Lancet Neurology.

[20]  V. V. Singh,et al.  Distinct Autoantibody Profiles in Systemic Lupus Erythematosus Patients are Selectively Associated with TLR7 and TLR9 Upregulation , 2013, Journal of Clinical Immunology.

[21]  L. Rönnblom,et al.  The interferon signature in autoimmune diseases , 2013, Current opinion in rheumatology.

[22]  Simon Yu,et al.  INTERFEROME v2.0: an updated database of annotated interferon-regulated genes , 2012, Nucleic Acids Res..

[23]  Andreas Radbruch,et al.  IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus , 2012, Annals of the rheumatic diseases.

[24]  H. Drexhage,et al.  Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression , 2012, Annals of the rheumatic diseases.

[25]  J. Casanova,et al.  Evolutionary genetic dissection of human interferons , 2011, The Journal of experimental medicine.

[26]  S. Greenberg,et al.  Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway , 2011, Annals of the rheumatic diseases.

[27]  J. Harley,et al.  Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[28]  L. Rönnblom,et al.  The type I interferon system in the development of lupus. , 2011, Seminars in immunology.

[29]  Tomoki Ito,et al.  Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA–Peptide Complexes in Systemic Lupus Erythematosus , 2011, Science Translational Medicine.

[30]  T. Hansen,et al.  The minor C-allele of rs2014355 in ACADS is associated with reduced insulin release following an oral glucose load , 2011, BMC Medical Genetics.

[31]  S. Marshall‐Clarke,et al.  Innate immune stimuli modulate bone marrow‐derived dendritic cell production in vitro by toll‐like receptor‐dependent and ‐independent mechanisms , 2010, Immunology.

[32]  D. Gladman,et al.  Lack of association between the interferon-α signature and longitudinal changes in disease activity in systemic lupus erythematosus , 2008, Annals of the rheumatic diseases.

[33]  T. Junt,et al.  Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. , 2006, Blood.

[34]  L. Rönnblom,et al.  Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. , 2006, Arthritis and rheumatism.

[35]  M. Crow,et al.  Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. , 2006, Arthritis and rheumatism.

[36]  C. Datz,et al.  Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon α mono and combination therapy regimens , 2005, Gut.

[37]  M. Peterson,et al.  Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. , 2005, Arthritis and rheumatism.

[38]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[39]  A. Meshorer,et al.  Involvement of interferon in virus-induced lymphopenia. , 1983, Cellular immunology.

[40]  Skurkovich Sv,et al.  The probable role of interferon in allergy. , 1975 .

[41]  Edinburgh Research Explorer Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease , 2022 .

[42]  D. Duffy,et al.  Edinburgh Research Explorer Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-Citation , 2018 .